Brief: VBI Vaccines Announces Presentation Of Interim Phase 2 Data Of VBI-2601 (BRII-179) & BRII-835
15/02/2023 14:10
Feb 15 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES PRESENTATION OF INTERIM PHASE 2
DATA
EVALUATING COMBINATION OF VBI-2601 (BRII-179) & BRII-835 FOR
TREATMENT OF CHRONIC HEPATITIS B
* VBI VACCINES INC - VBI-2601 (BRII-179) AND BRII-835
COMBINATION
WAS GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS OBSERVED
Source text for Eikon: ID:
Further company coverage: VBIV.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55